register

News & Trends - MedTech & Diagnostics

AMA, APHA, MTAA and CHF jointly raise serious concerns on proposed Prostheses List reforms

Health Industry Hub | February 24, 2021 |

MedTech News: The Australian Medical Association (AMA), Australian Private Hospitals Association (APHA), Consumer Health Forum (CHF), and the Medical Technology Association of Australia (MTAA) recognise the critical need for further reform of private health insurance in Australia to ensure its ongoing sustainability, including improvements to the Prosthesis List.

Reforms to the Prostheses List must focus on the needs of patients, including the preservation of access to the most clinically appropriate care.

Health Industry Hub‘s recent interviews with MTAA, Johnson & Johnson and Medtronic dive deeper into the significant concerns associated with the Department of Health’s proposed reform options to the current Prostheses List (PL).

The joint statement from AMA, APHA, MTAA and CHF noted that the existing PL protects patient access to the medical devices best suited to their needs as determined by their surgeon in consultation with the patient.

“We have come together to share our concerns and work towards a solution to the areas of the system not performing as intended. These reforms include:

  1. A robust, evidence-based and fit-for-purpose mechanism to underpin the listing and pricing of products, including provision for regular review to achieve savings,
  2. A clear definition of included products on the list,
  3. A simplified and more transparent list,
  4. Processes to review and promote evidence-based utilisation,
  5. More efficient access pathways, without compromising the rigour of appropriate and fit-for-purpose assessment processes, and
  6. Enhanced Department capabilities for list management.”

The Department’s proposal to abolish the PL and replace it with the private health insurance lobby’s preference of an AR-DRGs (Australia Revised – Diagnostic Reference Groups) based schedule of benefits, presents serious concern. This will mean hospitals are only funded to cover the cost of medical technology(s) used in an average case; i.e. the costs of devices in an average eye procedure, the cost of a knee joint and associated components in an average knee replacement.

This ignores the fact each patient and their health care needs are different – despite a similar diagnosis. The cost of the medical technologies required can vary significantly from patient to patient; even when they are undergoing the same procedure. This will leave patients and hospitals to pick up the cost for the difference, or simply miss out on accessing the necessary medical device/s.

By abolishing the PL and replacing it with an AR-DRG system, the Department would discourage Australians from continuing with their private health insurance, instead forcing them to rely on the public health system. This will place further strain on public hospitals and massively increase waiting times for procedures required by many elderly Australians, such as hip and knee replacements and lens replacements for cataract treatment.

The Department should be prioritising quality of outcomes for patients; preserving clinical choice; ensuring sustainability of the private health system and guaranteeing no out-of-pocket costs for their prosthesis. This can only happen by undertaking practical reform of the PL. The Department’s preferred approach of abolishing the PL and replacing it with a system unproven anywhere in the world will have detrimental impacts across both the public and private health systems.


News & Trends - Pharmaceuticals

Healthcare affordability and accessibility top priority for consumers ahead of Federal Budget

Healthcare affordability and accessibility top priority for consumers ahead of Federal Budget

Health Industry Hub | May 8, 2024 |

Pharma News: With the Federal Budget set to be delivered in just one week, there is a critical need for […]

More


News & Trends - Pharmaceuticals

UCB secures registration of rheumatology drug

UCB secures registration of rheumatology drug

Health Industry Hub | May 8, 2024 |

Pharma News: UCB Australia has secured Therapeutic Goods Administration (TGA) approval of its therapy for psoriatic arthritis (PsA), non-radiographic axial […]

More


Digital & Innovation

Targeted funding of digital health technologies key to unlocking $5 billion in savings: New report

Targeted funding of digital health technologies key to unlocking $5 billion in savings: New report

Health Industry Hub | May 8, 2024 |

Digital & Innovation: Integrating digital technology into healthcare more effectively could alleviate pressures on our healthcare system and lead to […]

More


News & Trends - MedTech & Diagnostics

Surgeons welcome 'significant win' for patients, amidst clash from health insurers

Surgeons welcome ‘significant win’ for patients, amidst clash with health insurers

Health Industry Hub | May 8, 2024 |

MedTech & Diagnostics News: The Royal Australasian College of Surgeons (RACS) is heralding a significant triumph for Australian patients following […]

More


This content is copyright protected. Please subscribe to gain access.